Development course
Development courseAnd key milestones
1997
■ The predecessor of Stelli Pharmaceutical - Zhejiang Taizhou Xianyuan Medicine and Health Products Co., LTD was established
2000
■ Mr. Hu Jinsheng and Mr. Wu Jinwei cooperated, renamed as Zhejiang Taizhou Staili Pharmaceutical Chemical Co., LTD., and successfully developed the first levofloxacin hydrochloride product
2003
■ Approved by Zhejiang Provincial Drug Administration, the company set up a pharmaceutical factory in Xianju Sanqiao and established Zhejiang Staili Pharmaceutical Co., LTD
2004
■ Obtained the "Drug Production License", in December of the same year, the company was assessed as a high-tech enterprise
2005
■ Iodohexyl alcohol products passed GMP certification for the first time and obtained pharmaceutical GMP certificate
2006
■ The new plant in Xianju County Modern Industrial Cluster Area broke ground and was changed to a Sino-foreign joint venture in December of the same year
2007
■ The new plant of the modern industrial Cluster area (Plant A) is officially put into operation
2008
■ The administrative center of the company was moved to the modern industrial agglomeration Zone A factory
2011
■ Jiangxi Staili Pharmaceutical Co., Ltd. was established
■ Completed the joint-stock transformation and established Zhejiang Staili Pharmaceutical Co., LTD
2012
■ Shanghai Steli Pharmaceutical Co., Ltd. was established
2015
■ Shanghai Keyhe Pharmaceutical Technology Co., Ltd. was established
2016
■ Listed on Shanghai Stock Exchange, stock code: 603520
■ Stari Investment (Hong Kong) Limited was established
■ Taizhou Sitai Basketball Club Co., Ltd. was established
2018
■ The administrative center of the company was moved to the B plant of the modern industrial agglomeration area
■ Acquired Zhejiang Taizhou Haishen Pharmaceutical Co., LTD
2020
■ The company's wholly-owned subsidiary Shanghai Stari Pharmaceutical Co., Ltd. declared the first products such as iopanol injection, iodohexyl injection and iodoxaxanol injection through the national new Class 4 registration (deemed to have passed the "drug consistency evaluation"), and obtained the registration approval of the State Drug Administration
2021
■ Zhejiang Sitaili Pharmaceutical Sales Co., Ltd. was established
About Starri
Product center
News information
Research and development
Social responsibility
Human resources
Official public account
Official mobile phone station
Copyright © 2019 Zhejiang Stelli Pharmaceutical Co., LTD. All Rights Reserved. Zhejiang ICP No. 18046522